Monitor for any future insider trading activity by the new CFO and track whether the leadership changes lead to improved execution on the vopimetostat development program. The appointments suggest the company is preparing for potential commercialization and may need additional capital in the future.
Price Chart
Executive Summary
Tango Therapeutics announced the appointment of Matthew Gall as Chief Financial Officer, effective April 15, 2026, replacing Daniella Beckman. The company also appointed Jessica Newcomb as principal accounting officer and introduced other leadership changes to support late-stage development of its drug vopimetostat. Gall's employment agreement includes a $540,000 base salary and equity awards.
Key Facts
- Matthew Gall appointed CFO effective April 15, 2026, replacing Daniella Beckman
- Gall's employment agreement includes $540,000 annual base salary and target bonus of 40% of base salary
- Gall to receive stock option for 240,000 shares and 40,000 restricted stock units
- Jessica Newcomb appointed principal accounting officer
- Additional appointments include Yen-Ching Chua as Chief Development Operations Officer and Janice Kapty as SVP, Corporate Strategy and Project Leadership
Financial Impact
Compensation package valued at approximately $540,000 base salary plus $216,000 target bonus and equity awards of 280,000 shares
Risk Factors
- Transition risk with new CFO and accounting officer
- Potential dilution from equity awards
- Execution risk in late-stage clinical development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-156127 |
| Document: d144586d8k.htm | 0001193125-26-156127 |
| Document: d144586dex991.htm | 0001193125-26-156127 |
| Document: 0001193125-26-156127-index-headers.html | 0001193125-26-156127 |
| Document: 0001193125-26-156127-index.html | 0001193125-26-156127 |
| Document: 0001193125-26-156127.txt | 0001193125-26-156127 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $25.58 $25.20 | ▲ +1.49% | ▲ +1.04% | $23.20 (+9.28%) |
Aug 11, 2026 7w ago | 8-K | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 11, 2026 7w ago | Press Release | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 9, 2026 7w ago | Institutional Cluster | $27.67 $25.29 | ▼ −8.60% | ▼ −8.55% | $23.20 (−16.14%) |
Aug 6, 2026 8w ago | 8-K | $27.07 $25.60 | ▼ −5.43% | ▼ −5.83% | $23.20 (−14.28%) |
Jun 11, 2026 16w ago | 144 | $30.94 $27.97 | ▼ −9.60% | ▼ −10.27% | $23.20 (−25.00%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 424B5 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 144 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access